“The company developing the drug, #RevolutionMedicines, presented results on May 31, 2026, from its Phase 3 clinical trial of 500 patients with metastatic #PancreaticCancer who had received prior treatment.
Compared to standard #chemotherapy, #daraxonrasib nearly doubled overall survival from 6.7 months to 13.2 months after diagnosis. Overall, daraxonrasib reduced the risk of death for metastatic pancreatic cancer patients by 60%.”

https://www.sciencealert.com/a-breakthrough-drug-just-achieved-the-impossible-for-pancreatic-cancer